Canaccord Genuity Maintains Buy on Exagen, Raises Price Target to $15
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $11 to $15.
Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $11 to $15.